Neuroprotective Effects of Cerebroprotein Hydrolysate on MPTP-induced Parkinson's Mice by Increasing Neurotrophin and Regulating Intestinal Microbiota

Yingjuan Liu^{1, 2}, Yuqian Ren^{1, 2}, Qinghua Zhang³, Leiming Ren⁴ and Guanxi Wang^{1, 5,}

¹Institute of Cerebrovascular Diseases, the Affiliated Hospital of Qingdao University, Qingdao 266003, China

²Shandong Provincial Collaborative Innovation Center for Neurodegenerative Disorders, Taishan Scholars Construction Project Excellent Innovative Team of Shandong Province, Qingdao 266003, China

³Department of Neurology，Shandong Second Provincial General Hospital，Jinan 250021

⁴Institute of Chinese integrative Medicine, Hebei Medical University, Shijiazhuang 050017, China.

⁵Songshan Hospital of Medical College, Qingdao University, Qingdao 266021, China

Cite this paper:
Yingjuan Liu, Yuqian Ren, Qinghua Zhang, Leiming Ren and Guanxi Wang. Neuroprotective Effects of Cerebroprotein Hydrolysate on MPTP-induced Parkinson's Mice by Increasing Neurotrophin and Regulating Intestinal Microbiota. Journal of Food and Nutrition Research. 2023; 11(8):533-539. doi: 10.12691/jfnr-11-8-3

Abstract

It is hypothesized that the neurotrophin loss and the intestinal tract could be a contributing factor to the neurodegenerative processes. Cerebroprotein hydrolysate-Ⅰ (CH-I), a mixture of amino acids and low molecular peptides had been reported to show remarkable therapeutic effect on many neurological diseases. However, the reports about the effects of cerebroprotein hydrolysate on PD was little. In this study, we applied CH-I on MPTP-induced mice to detect the neuroprotective effects. The results showed that CH-I could enhance the expression of neurotrophin (NGF and BDNF) and improve the behavioral deficits in MPTP-induced Parkinson's mice. Furthermore, CH-I restored the level of tyrosine hydroxylase (TH), and inhibited the apoptosis induced by MPTP. In addition, CH-I made a contribution to reducing the abundance of pathogenic microbiota and increasing the relative abundance of beneficial bacteria. The data demonstrate that CH-I shows promise as a novel treatment of PD.

Keywords:
Cerebroprotein hydrolysate-Ⅰ Parkinson’s disease intestinal microbiota neurotrophins mice

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Vascellari S, Palmas V, Melis M, et al. Gut microbiota and metabolome alterations associated with Parkinson’s Disease. mSystems. 2020;5(5): e00561-20.
[2]	Baluchnejadmojarad T, Rabiee N, Zabihnejad S, Roghani M. Ellagic acid exerts protective effect in intrastriatal 6-hydroxydopamine rat model of Parkinson's disease: Possible involvement of ERbeta/Nrf2/HO-1 signaling. Brain Res. 2017;1662:23-30.
[3]	Zhai S, Tanimura A, Graves SM, Shen W, Surmeier DJ. Striatal synapses, circuits, and Parkinson's disease. Curr Opin Neurobiol. 2017;48:9-16.
[4]	Wang YL, Ju B, Zhang YZ, et al. Protective Effect of Curcumin Against Oxidative Stress-Induced Injury in Rats with Parkinson's Disease Through the Wnt/ beta-Catenin Signaling Pathway. Cell Physiol Biochem. 2017;43(6):2226-2241.
[5]	Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson's disease in the United States. Mov Disord. 2013;28(3):311-8.
[6]	Ishii T, Kinoshita KI, Muroi Y. Serotonin 5-HT4 Receptor Agonists Improve Facilitation of Contextual Fear Extinction in an MPTP-Induced Mouse Model of Parkinson's Disease. Int J Mol Sci. 2019;20(21).
[7]	Lai F, Jiang R, Xie W, et al. Intestinal Pathology and Gut Microbiota Alterations in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease. Neurochem Res. 2018;43(10):1986-1999.
[8]	McCann H, Cartwright H, Halliday GM. Neuropathology of alpha-synuclein propagation and braak hypothesis. Mov Disord. 2016;31(2):152-160.
[9]	Heiko Braak , Kelly Del Tredici, Udo Rüb, Rob A.I. de Vos, Ernst N.H. Jansen Steur, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197-211.
[10]	Zhou B, Yuan Y, Zhang S, et al. Intestinal Flora and Disease Mutually Shape the Regional Immune System in the Intestinal Tract. Front Immunol. 2020;11:575.
[11]	Yang X, Liu L, Chen J, Xiao A. Response of Intestinal Bacterial Flora to the Long-term Feeding of Aflatoxin B1 (AFB1) in Mice. Toxins (Basel). 2017;9(10).
[12]	Lamouse-Smith ES, Tzeng A, Starnbach MN. The intestinal flora is required to support antibody responses to systemic immunization in infant and germ free mice. PLoS One. 2011;6(11):e27662.
[13]	Ma Q, Li Y, Li P, et al. Research progress in the relationship between type 2 diabetes mellitus and intestinal flora. Biomed Pharmacother. 2019;117:109138.
[14]	Wood H. Parkinson disease. Gut reactions--can changes in the intestinal microbiome provide new insights into Parkinson disease? Nat Rev Neurol. 2015;11(2):66.
[15]	van ISCD, Derkinderen P. The Intestinal Barrier in Parkinson's Disease: Current State of Knowledge. J Parkinsons Dis. 2019;9(s2):S323-S329.
[16]	Fang X. Microbial treatment: the potential application for Parkinson's disease. Neurol Sci. 2019;40(1):51-58.
[17]	Holzer P, Farzi A. Neuropeptides and the microbiota-gut-brain axis. Adv Exp Med Biol. 2014;817:195-219.
[18]	Holzer P, Reichmann F, Farzi A. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. Neuropeptides. 2012;46(6):261-274.
[19]	Liu Z, Wang W, Huang T, et al. CH(II), a cerebroprotein hydrolysate, exhibits potential neuro-protective effect on Alzheimer's disease. PLoS One. 2019;14(9):e0222757.
[20]	Sui R, Zang L, Bai Y. Administration of troxerutin and cerebroprotein hydrolysate injection alleviates cerebral ischemia/reperfusion injury by down-regulating caspase molecules. Neuropsychiatr Dis Treat. 2019;15:2345-2352.
[21]	Zhang X, Liu J, Wu L, Wang Z, Zhang S. GbWRKY1, a member of the WRKY transcription factor family identified from Gossypium barbadense, is involved in resistance to Verticillium wilt. Biotechnology & Biotechnological Equipment. 2019;33(1):1354-1364.
[22]	Hartbauer M, Hutter-Paier B, Skofitsch G, Windisch M. Antiapoptotic effects of the peptidergic drug Cerebrolysin on primary cultures of embryonic chick cortical neurons. J Neural Transm. 2001;108(4):459-473.
[23]	Noor NA, Mohammed HS, Mourad IM, Khadrawy YA, Aboul Ezz HS. A promising therapeutic potential of cerebrolysin in 6-OHDA rat model of Parkinson's disease. Life Sciences. 2016;155:174-179.
[24]	Zhou T, Zhu M, Liang Z. (-)-Epigallocatechin-3-gallate modulates peripheral immunity in the MPTP-induced mouse model of Parkinson's disease. Mol Med Rep. 2018;17(4):4883-4888.
[25]	Cao Q, Qin L, Huang F, et al. Amentoflavone protects dopaminergic neurons in MPTP-induced Parkinson's disease model mice through PI3K/Akt and ERK signaling pathways. Toxicol Appl Pharmacol. 2017;319:80-90.
[26]	Wan T, Wang Z, Luo Y, et al. FA-97, a New Synthetic Caffeic Acid Phenethyl Ester Derivative, Protects against Oxidative Stress-Mediated Neuronal Cell Apoptosis and Scopolamine-Induced Cognitive Impairment by Activating Nrf2/HO-1 Signaling. Oxid Med Cell Longev. 2019;2019:8239642.
[27]	Shamsaei N, Khaksari M, Erfani S, Rajabi H, Aboutaleb N. Exercise preconditioning exhibits neuroprotective effects on hippocampal CA1 neuronal damage after cerebral ischemia. Neural Regen Res. 2015;10(8):1245-1250.
[28]	J. Gregory Caporaso, Christian L. Lauber, William A. Walters, Donna Berg-Lyons, Catherine A. Lozupone, Peter J. Turnbaugh, et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4516-4522.
[29]	Taylor TN, Greene JG, Miller GW. Behavioral phenotyping of mouse models of Parkinson's disease. Behav Brain Res. 2010;211(1):1-10.
[30]	Jiang Q, Yan Z, Feng J. Neurotrophic factors stabilize microtubules and protect against rotenone toxicity on dopaminergic neurons. J Biol Chem. 2006;281(39):29391-29400.
[31]	Sadan O, Bahat-Stromza M, Barhum Y, Levy YS, Pisnevsky A, Peretz H, et al. Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease. Stem Cells Dev. 2009;18(8):1179-1790.
[32]	Hosp JA, Pekanovic A, Rioult-Pedotti MS, Luft AR. Dopaminergic projections from midbrain to primary motor cortex mediate motor skill learning. J Neurosci. 2011;31(7):2481-2487.
[33]	Winogrodzka A, Bergmans P, Booij J, van Royen E, Stoof JC, Wolters EC. 123I]β-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease. J Neurol Neurosurg Psychiatry Investig. 2017;74:294-298.
[34]	Yuan H, Sarre S, Ebinger G, Michotte Y. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. J Neurosci Methods. 2005;144(1):35-45.
[35]	Becker A, Fassbender K, Oertel WH, Unger MM. A punch in the gut - Intestinal inflammation links environmental factors to neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord. 2019;60:43-5.
[36]	Zhu G, Jiang Y, Yao Y, Wu N, Luo J, Hu M, et al. Ovotransferrin ameliorates the dysbiosis of immunomodulatory function and intestinal microbiota induced by cyclophosphamide. Food Funct. 2019;10(2):1109-1122.
[37]	Chen X, Sun H, Jiang F, et al. Alteration of the gut microbiota associated with childhood obesity by 16S rRNA gene sequencing. PeerJ. 2020;8:e8317.
[38]	Konya T, Koster B, Maughan H, et al. Associations between bacterial communities of house dust and infant gut. Environ Res. 2014;131:25-30.
[39]	Bedarf JR, Hildebrand F, Coelho LP, et al. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naive Parkinson's disease patients. Genome Med. 2017;9(1):39.
[40]	Zhao F, Feng J, Li J, et al. Alterations of the Gut Microbiota in Hashimoto's Thyroiditis Patients. Thyroid. 2018;28(2):175-186.